REG - Renalytix PLC - Partnership with MVP Health Care

RenalytixAnnouncement

17/07/2025 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250717:nRSQ3910Ra&default-theme=true

RNS Number : 3910R  Renalytix PLC  17 July 2025

Renalytix plc

("Renalytix" or the "Company")

 

Partnership with MVP Health Care
kidneyintelX.dkd now accessible for MVP's 700,000 members

 

LONDON and NEW YORK, 17 July 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY),
a precision medicine company with kidneyintelX.dkd
(https://www.kidneyintelx.com/) , the only FDA-approved and Medicare
reimbursed prognostic test to support early-stage risk assessment in chronic
kidney disease, and MVP Health Care (http://www.mvphealthcare.com/) ("MVP"), a
not-for-profit health insurer that provides services to 700,000 members in the
northeastern part of the United States, have joined forces to mitigate the
progression of chronic kidney disease in their insured type 2 diabetes patient
population.

 

Through this partnership, MVP and Renalytix will collaborate with physician
groups across MVP's network, with the goal of introducing and implementing
kidneyintelX.dkd advanced risk assessment testing. The test, which accurately
assesses patient-specific risk for progressive decline in kidney function,
enables clinicians to target resources, therapeutic options, and care plans
more appropriately, thereby increasing the chance for slowing disease
progression and improving patient outcomes, including those associated with
cardiovascular and metabolic comorbidities.

 

The kidneyintelX.dkd test, which is available to MVP's entire New York
membership, is FDA approved and is recommended for use by KDIGO, the
international kidney disease clinical guidelines.

 

Dr. Richard Dal Col, President of MVP Health Care, said: "At MVP Health Care,
we are committed to delivering innovative, affordable solutions that improve
access to care and support better health for our members. This partnership
with Renalytix reflects our mission to empower both providers and patients
with the tools they need to make informed, proactive decisions about their
health care journey. For our customers living with type 2 diabetes and CKD,
this means earlier insights, more personalized support, and a better path
forward."

 

James McCullough, CEO of Renalytix, said: "Forward-thinking in its approach,
we're proud to partner with MVP Health Care as they bring all parties to the
table to help solve the growing and costly CKD health epidemic. In healthcare
systems, and with individual providers, where kidneyintelX.dkd is deployed, we
are quantifiably mitigating CKD progression, while also demonstrating
HEDIS-measure improvements in blood pressure control and HbA1c levels in
high-risk patients."

 

 

For further information, please contact:

 

 Renalytix plc                                     www.renalytix.com (http://www.renalytix.com)
 James McCullough, CEO                             Via Walbrook PR

 SP Angel Corporate Finance LLP (Nominated Adviser and Joint Broker)                   Tel: +44 (0)20 3470 0470
 Jeff Keating / David Hignell (Corporate Finance)

 Vadim Alexandre (Corporate Broking)

 Oberon Capital (Joint Broker)                     Tel: +44 (0)20 3179 5300
 Mike Seabrook / Nick Lovering

 Walbrook PR Limited                               Tel: 020 7933 8780 or renalytix@walbrookpr.com
 Paul McManus / Alice Woodings                     Mob: 07980 541 893 / 07407 804 654

 

About Renalytix (www.renalytix.com (http://www.renalytix.com) )

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of kidney
disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now offered
commercially in the United States.

 

About MVP Health Care

MVP Health Care is a nationally recognized, not-for-profit health insurer
caring for members in New York and Vermont. Committed to the complete
well-being of the members and the communities it serves, MVP makes health
insurance more convenient, more supportive, and more personal.

 

For more information visit www.mvphealthcare.com
(http://www.mvphealthcare.com/)  or on Facebook
(https://www.facebook.com/MVPHealthCare/) , Twitter
(https://twitter.com/MVPHealthCare) , Instagram
(https://www.instagram.com/mvphealthcare/) , and LinkedIn
(https://www.linkedin.com/company/mvp-health-care/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDFQLLFEDLBBBK